AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00133250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab
Description: Abciximab bolus and infusion is given. Study medication includes 3 identical vials, each with 5 ml solution containing 10 mg abciximab. The bolus dose to be given should be rated at 0.125 ml/kg of patient's weight. After the bolus, a total dose of 0.045 ml/kg study substance (up to a maximal quantity of 3.6 ml) should be given over 12 hours.
Study NCT00133250 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Heparin Sodium
Description: Placebo bolus plus infusion is given. Study medication includes 3 identical vials, each with 5 ml solution containing 3000 U Heparin. The bolus dose to be given should be rated at 0.125 ml/kg of patient's weight. After the bolus, a total dose of 0.045 ml/kg study substance (up to a maximal quantity of 3.6 ml) should be given over 12 hours.
Study NCT02798367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-I plus placebo
Description: Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus placebo (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days)
Study NCT02798367 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CBT-I plus placebo
Description: Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus placebo (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days)
Study NCT02798367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBT-I plus Melatonin 3 mg
Description: Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus Melatonin 3 mg (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days.
Study NCT02798367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBT-I plus Melatonin 5 mg
Description: Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus Melatonin 5 mg (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days.
Study NCT03636334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based decision support system
Description: At intervention sites, physicians will receive training and support on use of the DSS, which will be installed on their local IT system. Individuals eligible for DSS at Intervention sites will be randomized or assigned to different drug sequence protocols for BP-lowering therapy using their current antihypertensive medications, co-morbidities, and intolerance to medications and according to the assignment plan in the Algorithm. If the protocol is not suitable for the patient because of new co-morbidities, medication intolerance or contraindication, the DSS will recommend switching to a new protocol.
Study NCT00933712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LACTIC ACID(ND)
Description: Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative for 6 weeks.
Study NCT03791593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Evolocumab is a human IgG2 monoclonal antibody, it will add to patient treatment during 12 months.
Study NCT04460807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane in addition to standard therapy, in Experimental arm.
Study NCT04460807 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo in addition to standard therapy, in Control arm.
Study NCT04079244 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video game
Description: Children receive a tablet with a video game at their arrival on the unit until the introduction of the anesthesia mask.~The video game used is Le Héros C'est Toi, a game specially developed for the unit. The game recreates the hospital environment and includes mini-games geared to children.
Study NCT04079244 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Animated cartoon
Description: Children receive a tablet with an animated cartoon at their arrival on the unit until the introduction of the anesthesia mask.~The cartoon used is L'âge de glace, an animated cartoon geared to children.
Study NCT00813657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Women in the intervention group were enrolled in three sessions/week of individually supervised, resistance exercise training performed over the second and third trimester of pregnancy (in total 26 weeks, \~80 training sessions). Heart rate (HR) was carefully and individually controlled (≤80% of age-predicted maximum HR value, 220-age) through a heart rate monitor during the training sessions. In brief, each session consisted of 35-40 minutes of exercise divided in a light intensity (≤60% maximal heart rate) warm-up period (\~8 minutes), followed by toning and very light resistance exercises (\~20 minutes) and a light intensity cool-down (\~8 minutes) period. Resistance exercises were performed with barbells (≤3kg per exercise) or low-to-medium resistance bands (Therabands).
Study NCT01294956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lubricant Eye Drop
Description: 1 drop in each eye, four times a day for 42 days
Study NCT01294956 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Refresh Liquigel
Description: 1 drop in each eye, four times a day for 42 days
Study NCT04400136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole oral tablets 30 mg
Description: Post operative prescription
Study NCT04342676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: vectibex in stage iv
Study NCT02969915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives
Description: Treatment incentives are offered to HIV-positive participants for reaching treatment targets, including retention to medical follow-up, initiating antiretroviral therapy, and maintaining high adherence with antiretroviral therapy.
Study NCT02623387 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided paravertebral block
Description: Paravertebral blocks is a regional anaesthetic technique in which thoracic spinal nerves are inhibited for post operative analgesia in patients undergoing breast surgery. The site of injection can be determined using anatomical landmarks (standard) or using ultrasound guidance.
Study NCT02969915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Care Centers
Description: ICCs offer key-population-oriented, vertically-integrated harm reduction, HIV testing, and HIV treatment services
Study NCT02969915 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Care Centers
Description: ICCs offer key-population-oriented, vertically-integrated harm reduction, HIV testing, and HIV treatment services
Study NCT03343678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax given alone and then in combination with BI 836826
Study NCT03343678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836826
Description: Venetoclax given in combination with BI 836826
Study NCT02238782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib 75mg single dose
Description: 3 capsules of 25 mg given as a single dose
Study NCT02238782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [14C] selumetinib IV solution
Description: single, radiolabeled, IV (infused), microdose (80 μg) of \[14C\] selumetinib, infused using a syringe pump as a 15-minute infusion, administered 1h 15 min after receiving the oral dose
Study NCT01656811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levalbuterol 90 mcg
Description: 90 mcg levalbuterol delivered via MDI 2 actuations of 45 mcg QID
Study NCT01656811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levalbuterol 180 mcg
Description: 180 mcg levalbuterol delivered via MDI 2 actuations of 90 mcg QID
Study NCT01656811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: racemic albuterol 180 mcg
Description: 180 mcg racemic albuterol delivered via MDI 2 actuations of 90 mcg QID
Study NCT01656811 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2 actuations QID
Study NCT00630708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benazepril
Description: 20 mg per day
Study NCT03276728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 986 IV
Description: AMG 986 solution for infusion
Study NCT03276728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 986 PO
Description: AMG 986 tablets for oral (PO) administration
Study NCT03276728 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PO
Description: Matching placebo tablets for oral administration
Study NCT03276728 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: Matching placebo solution for infusion
Study NCT00286091 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Administered by subcutaneous injection
Study NCT00286091 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same volume subcutaneous injection
Study NCT01994746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Glucagon
Study NCT01994746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular Glucagon
Study NCT02402530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo administered as intravenous infusion.
Study NCT02402530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered as intravenous infusion.
Study NCT02402530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neridronic acid 62.5 mg
Description: Neridronic acid administered as intravenous infusion.
Study NCT01060904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 0.6-1.2 mg/kg IV every 2 weeks
Study NCT01060904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 25 mg/m2 IV every 2 weeks
Study NCT01060904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine
Description: 6 mg/m2 IV every 2 weeks
Study NCT01060904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Description: 375 mg/m2 IV every 2 weeks
Study NCT01060904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bleomycin
Description: 10 units/m2 IV every 2 weeks
Study NCT01060904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 0.9-1.2 mg/kg IV every 2 weeks
Study NCT03343340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early CRRT
Description: Continous Renal Replacement Therapy
Study NCT03343340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Late CRRT
Description: Continous Renal Replacement Therapy
Study NCT03343340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Therapy
Description: Standard Medical Therapy
Study NCT00630708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: 100 mg per day
Study NCT03343340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Therapy
Description: Standard Medical Therapy
Study NCT00630708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benazepril+Losartan
Description: combination treatment of 10 mg benazepril and 50 mg losartan per day
Study NCT04516733 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: supportive care
Description: visit with supportiv unit and neuropsychologue every 3 months
Study NCT03704805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Friendship bench intervention
Description: The friendship bench intervention consists of six individual counseling sessions and a peer-led group activity. Individual counseling is based on problem-solving therapy and delivered by lay health workers. During individual counseling, participants will be actively encouraged to identify and tackle problems leading to sub-optimal antiretroviral therapy adherence. In the group activity, participants are taught an income generating skill and have the opportunity to share personal experience with former participants of the intervention.
Study NCT03704805 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Standard of Care
Description: Study participants receive information on available routine services for common mental disorders, a nurse-led brief support counseling, assessment for antidepressant medication (fluoxetine) by the clinic nurse, and referral to a psychiatric facility if needed, in addition to the standard of care provided according to national antiretroviral therapy guidelines.
Study NCT03704805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Standard of Care
Description: Study participants receive information on available routine services for common mental disorders, a nurse-led brief support counseling, assessment for antidepressant medication (fluoxetine) by the clinic nurse, and referral to a psychiatric facility if needed, in addition to the standard of care provided according to national antiretroviral therapy guidelines.
Study NCT00248105 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Physical Activity Management
Description: Lifestyle Physical Activity Promotion as given by Physical Activity Advocates. Advocates will meet with participants at baseline and every 3 months throughout the study to promote increase in lifestyle physical activity reached through goal setting and Motivational Interviewing (MI)
Study NCT04090580 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring
Description: Subjects enrolled will be randomized 1:1 to either receive a daily dosage of dapagliflozin 10 mg and 2000 mg metformin for 12 weeks (n=18) or 2000 mg metformin (n=18). Patients who do not tolerate metformin at 2000mg dose will be downtitrated to 1500 mg daily. In case patients do not tolerate 1500 mg daily, they will be excluded.~Both groups will be monitored for 7 days using either iPro™ CGM system (Medtronic, Northridge, CA) or Dexcom G6 CGM (Dexcom Inc, San Diego, CA). Basal continuous glucose monitoring will start at week 1 (first visit), and removed at day 7 and final continuous glucose monitoring will start at week 11 and removed 7 days after (final visit).
Study NCT02228824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Very low nicotine content cigarettes
Description: 0.07 mg nicotine delivery
Study NCT02228824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal nicotine content cigarettes
Description: 0.8 mg nicotine delivery
Study NCT02658838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Patients were treated with full amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
Study NCT04503512 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: removal of fat pad
Description: Removal removal of fat pad
Study NCT04503512 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non removal of fat pad
Description: non removal of fat pad
Study NCT01978600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension
Description: Commercially marketed and approved for lowering IOP in patients with open-angle glaucoma and ocular hypertension.
Study NCT01978600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol Maleate 0.5%
Description: Commercially marketed and approved for lowering IOP in patients with open-angle glaucoma and ocular hypertension.
Study NCT02658838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: full amount low molecular weight heparin
Description: Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
Study NCT02658838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: half amount low molecular weight heparin
Description: Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
Study NCT06023121 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of levels of an exosome-based liquid biopsy signature
Description: Each participant was enrolled to assess the levels of an exosome-based liquid biopsy signature
Study NCT01495533 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: uncoated AngioSculpt(R)
Description: Predilatation of coronary BMS-ISR with POBA followed by a AngioSculpt(R) scoring balloon (no drug coating)
Study NCT01495533 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Drug coated AngioSculpt(R)
Description: Predilatation of coronary BMS-ISR with POBA followed by a drug coated AngioSculpt(R) scoring balloon (paclitaxel 3.0 µg/mm²)
Study NCT02175485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 30 mg+Pseudophedrine HCl 60 mg
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT04308655 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Semi-structured interviews
Study NCT04308655 — intervention group
Intervention type: OTHER
Intervention: Surveys
Description: Validated surveys on pain, fear, anxiety, depression, beliefs
Study NCT01295944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be given on day 1 of each cycle; the carboplatin dose should be calculated using the Calvert formula: Carboplatin dose (mg) = target Area Under the Curve (AUC) x (Creatinine clearance (CrCl) + 25; The total duration of treatment will be 6 cycles. After cycle 6, carboplatin should be discontinued.
Study NCT01295944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered on days 1 and 15 of each cycle. Bevacizumab will be administered at a dose of 10 mg/kg; The total duration of treatment will be 6 cycles. After cycle 6, bevacizumab may be continued at the discretion of the treating physician.
Study NCT02658838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No low molecular weight heparin
Description: Patients were treated with no low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
Study NCT01022944 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: With chronic middle ear effusion
Description: Children with chronic middle ear effusion having adenoidectomy.
Study NCT01022944 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Without chronic middle ear effusion
Description: Children without chronic middle ear effusion as a control group having adenoids removed for chronic obstruction.
Study NCT04140435 — intervention group
Intervention type: DEVICE
Intervention: EUS-guided through-the-needle microbiopsy forceps (Moray)
Description: EUS-TTNB procedure technique. An endosonographer of each institution will perform the EUS procedures. Cysts morphology will be recorded and then punctured by using a 19-gauge EUS-FNA needle. Then the through-the-needle microbiopsy forceps (Moray) will be inserted through the needle into the cystic lumen. Microbiopsies will be obtained from the cyst wall randomly and from mural nodules or septae when observed. The open jaws of the forceps will be pushed onto the cyst wall, closed and pulled back to cause visible tenting. Two bites per pass will be obtained. Then the forceps will be removed and the specimen placed in formalin vials. The procedure will be repeated 2 times, or until 2 visible specimens are obtained. After completion of biopsies, the cyst fluid will be completely aspirated and sent for CEA, amylase, glucose and cytology analyses. If a mural nodule is visualized on EUS, it will be accessed separately by using the 19-gauge needle for EUS-FNA cytology.
Study NCT03312595 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Restrata TM Wound Matrix
Description: The RestrataTM Wound Matrix is a sterile, single use device intended for use in local management of wounds
Study NCT02320760 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity on prescription
Study NCT00420459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: All subjects will initially receive 2.5 mg/day of aripiprazole during the first week. The dosage may be increased to a maximum of 20 mg/day over 8 weeks.
Study NCT02884401 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Dental implant placement (Straumann® Bone Level Tapered, BLT, Roxolid® SLActive®)
Description: A tapered bone level implant (Straumann® BLT Roxolid® SLActive®, Basel, Switzerland) will be placed according to the manufactures guidelines trying to achieve primary stability in the correct prosthetic position
Study NCT03870282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension
Description: The intervention is designed to test if sleep tips delivered by text messages can aid with reaching sleep targets. And if additional motivational text messages can further aide with reaching sleep targets.
Study NCT03685968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video laryngoscopes
Description: Patients were randomized into one of the three groups through a computer generated randomization schedule. Patients in group A (N= 75) will be intubated using the GlideScope® AVL, patients in group B (N= 75) will be intubated using the King Vision Channeled VL; patients in group C (N=75) will be intubated using the King Vision Video Laryngoscope with Standard (non-channeled) Blade. Patients will only be tested with one device. All patients will be intubated using a conventional ETT.